• Moderate to Severe Obesity (BMI ≥30 kg/m2 or ≥27 kg/m2 with Comorbidities) • Preference for non-surgical treatment, due to either preference or contraindications • Adjunct to lifestyle modifications for those willing to change lifestyle alongside pharmacotherapy • Good response to GLP-1 Agonists. This evidence concerns the gene GLP1R and Obesity.